Healthpeak Properties, Inc. DOC reported first-quarter 2024 funds from operations (FFO) as adjusted per share of 45 cents, beating the Zacks Consensus Estimate by a penny. The reported figure rose 7.1% from the prior-year quarter. Results reflect better-than-anticipated revenues. Moreover, growth in total merger-combined same-store cash (adjusted) net operating income (NOI) was witnessed across the portfolio. The company also revised its 2024 outlook. The healthcare real estate investment trust (REIT) generated revenues of $606.6 million, outpacing the Zacks Consensus Estimate of $555.5 million. Moreover, the figure climbed 15.4% year over year. Behind the Headlines In the first quarter, Healthpeak reported 4.5% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI. It witnessed 2.6% and 2.7% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI for its outpatient medical and lab segments, respectively. The CCRC segment reported growth of 26.6%. During the reported quarter, Healthpeak executed lab new and renewal leases totaling 155,000 square feet. For the outpatient medical portfolio, new and renewal leases aggregated 1.4 million square feet. Balance Sheet Healthpeak exited the first quarter with cash and cash equivalents of $101.8 million, down from $117.6 million as of Dec 31, 2023. Its net debt to adjusted EBITDAre was 5.2X as of Mar 31, 2024. Dividend Update Concurrent with its first-quarter earnings release, Healthpeak’s board of directors announced a quarterly cash dividend of 30 cents per common share. The dividend will be paid out on May 17 to shareholders on record as of May 6, 2024. 2024 Outlook Healthpeak revised its guidance for FFO as adjusted per share to the range of $1.76-$1.80 from $1.73-$1.79 estimated earlier. The Zacks Consensus Estimate for the same is presently pegged at $1.77, which is within expectations. The total merger-combined same-store cash (adjusted) NOI growth is revised and estimated to be in the range of 2.50-4.00% from 2.25-3.75%. Healthpeak currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Healthpeak Properties, Inc. Price, Consensus and EPS Surprise Healthpeak Properties, Inc. Price, Consensus and EPS Surprise Healthpeak Properties, Inc. price-consensus-eps-surprise-chart | Healthpeak Properties, Inc. Quote Performance of Other REITs Alexandria Real Estate Equities, Inc. ARE reported first-quarter 2024 adjusted funds from operations (AFFO) per share of $2.35, which beat the Zacks Consensus Estimate of $2.31. The reported figure also climbed 7.3% from the year-ago quarter. Results reflected a rise in revenues, aided by decent leasing activity and rental rate growth. Alexandria also narrowed its 2024 outlook. Crown Castle CCI reported first-quarter 2024 AFFO per share of $1.72, outpacing the Zacks Consensus Estimate by a penny. Results reflected better-than-anticipated revenues, with the company reporting net revenues of $1.64 billion, beating the Zacks Consensus Estimate of $1.63 billion. However, on a year-over-year basis, AFFO per share declined 9.9% while revenues fell 7.4%. Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Crown Castle Inc. (CCI):Free Stock Analysis Report Alexandria Real Estate Equities, Inc. (ARE):Free Stock Analysis Report Healthpeak Properties, Inc. (DOC):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Healthpeak's (DOC) Q1 FFO Beat Estimates, Same-Store NOI Up
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...